Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01734694 · ClinicalTrials.gov registry record · Phase 4
Safety and Efficacy of Strategy to Prevent Drug-Induced Nephrotoxicity in High-Risk Patients
A Phase 4 study, sponsored by Henry Ford Health System.
- Terminated
- Registry status
- Phase 4
- Development phase
- 100
- Enrollment target
NCT01734694: Clinical Trial Phase 4 study, sponsored by Henry Ford Health System.
NCT01734694 is a Phase 4 study that was terminated before completion, run by Henry Ford Health System. The registered enrollment target is 100 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (81% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01734694, a Phase 4 study, was terminated before completion, sponsored by Henry Ford Health System.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 100 participants
- Enrollment target
Study Summary
For more than fifty years, vancomycin has been cited as a nephrotoxic agent. Reports of vancomycin induced kidney injury (a.k.a vancomycin induced nephrotoxicity or VIN), have waxed and waned throughout the years for various reasons. Recently, VIN has reemerged as a clinical concern. This may be due to various reasons, including new dosing recommendations as well as an increased prevalence of risk factors associated with vancomycin induced nephrotoxicity. This study aims to evaluate a strategy which attempts to reduce kidney damage from vancomycin use.
Primary Outcome
Increase in SCr of 0.5 mg/dL or 50% above baseline for at least two consecutive days while on the study drug and through discharge from hospital. This measure will be reported as proportion of patients with nephrotoxicity within each group in relation to the number of patients in each group.
Interventions
- DRUG Vancomycin
- DRUG Ceftaroline
- DRUG Linezolid
- DRUG Daptomycin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2011-10 |
| Est. Completion | 2012-09 |
| Phase | Phase 4 |
Why NCT01734694 stopped before completion
NCT01734694 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (81% lower).
The record links to 0 conditions, and to 4 interventions - of which Vancomycin is the first listed.
NCT01734694 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01734694 about?
NCT01734694 is a clinical study titled "Safety and Efficacy of Strategy to Prevent Drug-Induced Nephrotoxicity in High-Risk Patients". For more than fifty years, vancomycin has been cited as a nephrotoxic agent. Reports of vancomycin induced kidney injury (a.k.a vancomycin induced nephrotoxicity or VIN), have waxed and waned throughout the years for various reasons. Recently, VIN has reemerged as a clinical concern. This may be due...
What is the current status of trial NCT01734694?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 100 participants. The study started on 2011-10. Estimated completion is 2012-09.
What interventions are being tested in trial NCT01734694?
The interventions under investigation include: Vancomycin (DRUG), Ceftaroline (DRUG), Linezolid (DRUG), Daptomycin (DRUG).
Who is sponsoring clinical trial NCT01734694?
This trial is sponsored by Henry Ford Health System, which has 234 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01734694's enrollment target sits among peer trials
100 770th of 2000 higher than 1,148 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia